Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia ...

The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 ...

Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has accepted their supplemental new drug application (sNDA) for INQOVI ...

Taiho Pharmaceutical’s investigational treatment for Duchenne muscular dystrophy (DMD) has failed to impact the time it takes patients to rise from the floor over 52 weeks, missing the phase 3 ...

Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company ...

DelveInsight's Claudin 18.2 Directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report ...

PURPOSEWe investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor–positive (HR+) BC who had a live birth in the POSITIVE ...

Renowned Penn scientist Carl June and Jeff Marrazzo, founding CEO of Philly's Spark Therapeutics, are part of the leadership ...

BERLIN, July 08, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer and eye ...

Taiho Oncology and Taigo Pharmaceutical announce US FDA acceptance of Supplemental New Drug Application for Inqovi® in combination with venetoclax to treat patients with acute myeloid leukemia.

Telangana pharma factory blast news: Follow live updates on the Sigachi Industries explosion that killed over 30 people in a tragic incident.